FDA
-
-
-
-
-
-
-
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
-
-
-
-
-
-
-
Abeona receives permanent J-code for ZEVASKYN gene therapy
-
-
-
-
-
-
-
Abeona gene therapy selected for FDA rare disease pilot program
-
-
-
-
-
-
-
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
-
-
-
-
-
-
-
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
-
-
-
-
-
-
-
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

